Skip to content

China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-right Heart Catheterization

China Pulmonary Vascular Disease Intervention Diagnosis and Management Study-A Quality Control on Right Heart Catheterization

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06954727
Acronym
CHA-RHC
Enrollment
10000
Registered
2025-05-02
Start date
2018-01-01
Completion date
2030-12-31
Last updated
2025-05-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Arterial Hypertension, Pulmonary Embolism (Diagnosis), Pulmonary Hypertension, Right Heart Catheterization

Keywords

right heart catheterization, pulmonary hypertension, pulmonary arterial hypertension, pulmonary vascular disease

Brief summary

Right heart catheterization(RHC) plays a crucial role in the diagnosis and treatment of pulmonary vascular diseases(PVD). In China, the lack of equipment and technical expertise has historically limited the implementation of RHC, thereby greatly restricting the diagnosis and treatment of RVD. In recent years, with improvements in these issues, more hospitals have acquired the capability to perform RHC. The purpose of this study is to conduct quality control of RHC across multiple pulmonary hypertension(PH) centers in China. The study population consists of patients who underwent RHC for the first time due to dyspnea or suspected PH. This study retrospectively and prospectively collects multicenter RHC data, with the main quality control contents including indications for the procedure, collection and analysis of hemodynamic data, diagnosis and treatment, and long-term management of patients.

Detailed description

This study is led by the China-Japan Friendship Hospital and will be conducted across approximately 30 pulmonary hypertension centers in China. It is an observational cohort study without interventional treatment. Eligible participants are patients aged 14 years or older who undergo right heart catheterization due to dyspnea or suspected pulmonary hypertension. After study initiation, investigators at each center will enroll eligible patients and collect baseline data, hemodynamic parameters from right heart catheterization, diagnostic classification of pulmonary hypertension, and treatment plans. Patients will receive routine follow-up at their respective centers, and investigators will gather follow-up data according to the study protocol. All de-identified data will be recorded in an Electronic Data Capture (EDC) system. A dedicated data management team will oversee data management, quality control, and statistical analysis.

Interventions

No intervention; observational study

Sponsors

China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
14 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients who underwent right heart catheterization for the first time due to dyspnea or suspected pulmonary hypertension * Age ≥14 years old

Exclusion criteria

* Vital data missing * Did not sign informed consent or did not agree to follow-up

Design outcomes

Primary

MeasureTime frameDescription
3-month all cause death3 month3-month all cause death

Secondary

MeasureTime frameDescription
dignosis and type of pulmonary hypertension1 monthdignosis and type of pulmonary hypertension according to latest guidelines
1-year all cause death1 year1-year all cause death

Countries

China

Contacts

Primary ContactZhenguo Zhai
zhaizhenguo2011@126.com010-8420-6265
Backup ContactYu Zhang, MD
zhangyuccmu2013@yeah.net+8613120211583

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026